What is the stability of rhIL - 11 injection vial under different temperatures?
As a supplier of rhIL - 11 injection vials, understanding the stability of our product under different temperatures is of utmost importance. This knowledge not only ensures the quality and efficacy of the product but also helps in proper storage and transportation, which are crucial aspects of the pharmaceutical supply chain.
Significance of Temperature Stability in rhIL - 11 Injection Vials
rhIL - 11, or recombinant human interleukin - 11, is a cytokine that plays a vital role in hematopoiesis and megakaryocytopoiesis. It is commonly used to prevent severe thrombocytopenia in patients undergoing chemotherapy. The stability of rhIL - 11 in injection vials is directly related to its biological activity and safety. If the temperature conditions are not well - controlled, the protein structure of rhIL - 11 may be altered, leading to a decrease in its activity or the formation of aggregates, which can potentially cause adverse reactions in patients.
Temperature Ranges and Their Effects
Low - Temperature Conditions
At low temperatures, typically around 2 - 8°C, which is the standard refrigeration temperature for many biological products, rhIL - 11 injection vials generally show good stability. The low temperature slows down the rate of chemical reactions and microbial growth. Proteins are less likely to denature at these temperatures, and the integrity of the formulation in the vial is maintained. However, it is important to note that freezing temperatures should be avoided. Freezing can cause the formation of ice crystals, which can damage the protein structure and the vial itself. When water freezes, it expands, and this expansion can lead to cracks in the vial or changes in the physical properties of the formulation.
Room - Temperature Conditions
Room temperature, usually defined as 20 - 25°C, presents a more challenging environment for rhIL - 11 injection vials. At these temperatures, the rate of chemical degradation and microbial growth increases. The protein may start to unfold, leading to a loss of its biological activity. Additionally, the risk of contamination is higher at room temperature. Some studies have shown that prolonged exposure to room temperature can lead to a significant decrease in the potency of rhIL - 11 over time. However, short - term exposure to room temperature, such as during transportation or when the vial is being prepared for use, may be acceptable as long as the total exposure time is limited.
High - Temperature Conditions
High temperatures, above 30°C, can have a severe impact on the stability of rhIL - 11 injection vials. At these temperatures, the protein degradation rate accelerates rapidly. The secondary and tertiary structures of the protein are more likely to be disrupted, resulting in a complete loss of biological activity. Microbial growth also becomes a major concern at high temperatures. Bacteria and fungi can multiply quickly, and if the vial is contaminated, it can pose a serious threat to patient safety. Even short - term exposure to high temperatures can cause irreversible damage to the product.
Experimental Studies on Temperature Stability
To accurately assess the stability of rhIL - 11 injection vials under different temperatures, we have conducted a series of experimental studies. In these studies, we placed the vials in temperature - controlled chambers set at different temperatures (2 - 8°C, 20 - 25°C, and 30 - 35°C) for a specific period of time. We then analyzed the samples at regular intervals to measure the concentration of rhIL - 11, its biological activity, and the presence of any aggregates or impurities.
The results of these studies showed that at 2 - 8°C, the concentration and activity of rhIL - 11 remained relatively stable over a long period of time. There were only minor changes in the protein structure, and the level of impurities was within the acceptable range. At room temperature, the activity of rhIL - 11 started to decline after a few weeks, and the concentration of aggregates increased slightly. At high temperatures, the decline in activity was much more rapid, and significant amounts of aggregates and impurities were detected within a few days.
Implications for Storage and Transportation
Based on our understanding of the temperature stability of rhIL - 11 injection vials, proper storage and transportation guidelines have been established. For long - term storage, the vials should be kept in a refrigerator at 2 - 8°C. During transportation, cold chain logistics should be employed to ensure that the temperature remains within the acceptable range. Specialized temperature - controlled containers and vehicles are used to maintain the required temperature. If short - term exposure to room temperature is unavoidable, it should be minimized as much as possible.
Comparison with Other Oncology Injections
In the field of oncology, there are many other injection products, each with its own temperature stability requirements. For example, Daratumumab (with Recombinant Human Hyaluronidase) injection, CAS No.: 945721 - 28 - 8 is a monoclonal antibody used in the treatment of multiple myeloma. It also requires careful temperature control during storage and transportation to maintain its stability and efficacy. Similarly, PegFilgrastim Injection – A Long Lasting RhG - CSF, CAS No.: 208265 - 92 - 3, Bulk and Injection (PFS): 6mg in 0.6ml and Fulvestrant Injection – An Anti - cancer Drug, CAS No.: 129453 - 61 - 8, Bulk and Injection (PFS): 250mg in 5ml have specific temperature requirements to ensure their quality.
Conclusion and Call to Action
In conclusion, the stability of rhIL - 11 injection vials under different temperatures is a critical factor that affects the quality, efficacy, and safety of the product. By understanding the impact of different temperature ranges on the product, we can implement appropriate storage and transportation measures to ensure that the rhIL - 11 reaches the patients in the best possible condition.
If you are interested in purchasing high - quality rhIL - 11 injection vials with strict temperature - controlled manufacturing and supply processes, we invite you to contact us for procurement discussions. Our team of experts is ready to provide you with detailed information and support to meet your specific needs.
References
- "Stability of Biopharmaceuticals: An Overview" by John M. Anderson.
- "Temperature - Related Degradation of Protein Therapeutics" in the Journal of Pharmaceutical Sciences.
- Research studies on the stability of rhIL - 11 conducted by our in - house research team.